Morgan Stanley’s Opiant Pharmaceuticals OPNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-197,652
Closed -$4.01M – 7937
2022
Q4
$4.01M Hold
197,652
– – ﹤0.01% 3941
2022
Q3
$77K Sell
7,211
-1,546
-18% -$17.5K ﹤0.01% 6212
2022
Q2
$105K Hold
8,757
– – ﹤0.01% 6250
2022
Q1
$571K Sell
26,675
-7,661
-22% -$203K ﹤0.01% 5330
2021
Q4
$1.15M Buy
34,336
+18,547
+117% +$517K ﹤0.01% 4965
2021
Q3
$406K Buy
15,789
+7,028
+80% +$126K ﹤0.01% 5622
2021
Q2
$117K Sell
8,761
-715
-8% -$8.84K ﹤0.01% 6285
2021
Q1
$101K Buy
9,476
+1,000
+12% +$11.4K ﹤0.01% 6007
2020
Q4
$68K Sell
8,476
-2,238
-21% -$17.6K ﹤0.01% 6058
2020
Q3
$80K Buy
10,714
+3,012
+39% +$26.7K ﹤0.01% 5529
2020
Q2
$69K Buy
7,702
+3,160
+70% +$32.8K ﹤0.01% 5558
2020
Q1
$44K Buy
4,542
+989
+28% +$11.8K ﹤0.01% 5518
2019
Q4
$51K Buy
3,553
+676
+23% +$9.9K ﹤0.01% 5852
2019
Q3
$43K Sell
2,877
-19,537
-87% -$272K ﹤0.01% 5790
2019
Q2
$297K Buy
22,414
+20,377
+1,000% +$247K ﹤0.01% 4850
2019
Q1
$26K Buy
2,037
+606
+42% +$8.83K ﹤0.01% 5929
2018
Q4
$21K Sell
1,431
-862
-38% -$14.1K ﹤0.01% 6004
2018
Q3
$41K Buy
2,293
+1,803
+368% +$31.2K ﹤0.01% 5929
2018
Q2
$7K Buy
490
+130
+36% +$2.29K ﹤0.01% 6379
2018
Q1
$7K Sell
360
-3,178
-90% -$68.7K ﹤0.01% 6347
2017
Q4
$81K Buy
3,538
+639
+22% +$20.5K ﹤0.01% 5703
2017
Q3
$107K Buy
+2,899
New +$108K ﹤0.01% 5557

Morgan Stanley's OPNT Position: Q1 2023 in Review

Morgan Stanley sold out of Opiant Pharmaceuticals (OPNT) in Q1 2023, closing a stake of 197,652 shares — an estimated $4.01M sold.

Morgan Stanley first reported a position in OPNT in Q3 2017 and held it in 22 quarters. The position peaked at $4.01M in Q4 2022. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.

  • Morgan Stanley reported no remaining Opiant Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Morgan Stanley sold 197,652 Opiant Pharmaceuticals shares in Q1 2023, an estimated $4.01M.
  • Morgan Stanley first reported a position in Opiant Pharmaceuticals in Q3 2017 and held it in 22 quarters.
  • Morgan Stanley's Opiant Pharmaceuticals position peaked at $4.01M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals as of Q1 2023.

Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.